ArticleBMC medical genomics2026
Gender-wise distribution of metabolic risk factors and their relationship with fibroblast growth factor 1 and gene polymorphism (rs152524).
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-communicable diseases (NCDs) account for over 70% of deaths worldwide, and metabolic risk factors such as obesity, dyslipidemia, and hypertension greatly increase the incidence of NCDs. Lifestyle changes have exacerbated these conditions in Pakistan; therefore, a better knowledge of their underlying mechanisms is required. This study investigates the relationship between fibroblast growth factor 1 (FGF1) blood levels, the rs152524 gene polymorphism, and metabolic risk factors.
methodWe conducted a hospital-based, cross-sectional study of 199 adults recruited from outpatient departments between September 2023 and June 2024. After written informed consent, demographic, medical, and biochemical data were collected. FGF1 rs152524 was genotyped using tetra-primer ARMS PCR and serum FGF1 levels were quantified by ELISA at the National Health Research Complex and Lahore College for Women University. Statistical analyses were performed using SPSS v.26; p < 0.05 was considered significant.
resultsThere were no significant differences in age or BMI between males and females. However, females demonstrated significantly higher median (IQR) of FGF1 levels [333 pg/ml (250-467) vs. 292 pg/ml (212-374); p = 0.011]. Fasting blood glucose, LDL-cholesterol and hypertension were the three main predictors of FGF1 levels, according to regression analysis. Within the participant population, 38.7% carried the AA genotype of rs152524. The allelic frequencies of reference A and alternative G alleles were 0.5955 and 0.4045 respectively. AA genotype was substantially associated with both hypertension (p < 0.001) and overweight/obesity (p = 0.002). The highest median (IQR) FGF1 blood levels 351(263-546) pg/ml were observed among AA genotype carriers. At the same time, a substantial rise in HDL-cholesterol 36(32-42) was found among carriers of the GG genotype.
conclusionThis hospital-based study identified a potential association between the FGF1 rs152524 AA genotype and obesity and hypertension. The AA genotype was present in 38% of participants, with risk rising per 'A' allele, while the G allele appeared protective. These preliminary findings require validation in larger, population-based cohorts before clinical relevance can be assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.